Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference

November 12, 2014 – 11:00 am | Edit Post

SAN DIEGO, Nov. 12, 2014 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in London.

The live presentation takes place on Wednesday, November 12 at 3:40pm in London (7:40am PT/10:40am ET).  The presentation will be webcast and may be accessed on the Company’s website at http://www.neurocrine.com.

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.  The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.  Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.  Neurocrine Biosciences, Inc. news releases are available through the Company’s website via the internet at http://www.neurocrine.com.
SOURCE Neurocrine Biosciences, Inc.

IBM Watson Group Invests in Pathway Genomics to Help Personalize Consumer Health

November 12, 2014 – 9:00 am | Edit Post

NEW YORK and SAN DIEGO, Nov. 12, 2014 /PRNewswire/ — Cognitive apps are in market today and continue to change the way professionals and consumers make decisions. To help accelerate this transformation, the IBM Watson Group announced an investment in Pathway Genomics Corporation, a clinical laboratory that offers genetic testing services globally, to help deliver the first-ever cognitive consumer-facing app based on genetics from a user’s personal makeup.

This brings Pathway Genomics’ funding in the last six years to more than $80 million, making it one of the industry’s best capitalized start-up healthcare companies. In October, Pathway Genomics was included in Inc. magazine’s Coolest Products of the Inc. 500. The genetic test was ranked in the top 12 services and products from 5000 companies across the nation.

According to Allied Market Research, the bioinformatics market, which includes genetics, is expected to grow to $12.86 billion by 2020. IBM (NYSE: IBM) and Pathway are on the cutting edge of offering truly personalized wellness information.

Pathway Genomics is aiming to revolutionize the health and wellness industry by leveraging the natural language processing and cognitive capabilities of Watson. For the first time consumers will be able to ask the Pathway Panorama app questions to gain insights and options powered by the cognitive intellect of Watson, based on their own wellness-related genes, wearable data, and other related wellness information, like emotional, physical and social well being.

The new mobile app, Pathway Panorama, will be designed to call upon Watson’s unique ability to uncover insights from Big Data by understanding the complexities of human language, referencing millions of pages of healthcare data from medical journals and clinic trial data within seconds. The data will be combined with information about the individual’s lifestyle and wellness-related biomarker data to provide personalized options to help the user and their physician make informed decisions about living a healthier life. Panorama will also routinely monitor a user’s health and wellness information, and ping the user with any new relevant recommendations.

For example, a consumer will be able to ask the Pathway Panorama app questions based on their DNA, like “How much exercise should I do today?” to “How much coffee can I drink on Monday?” The cognitive app answers and provides options based on the millions of healthcare-related evidence-based data, provided by Pathway Genomics, ingested by Watson and on the individual’s biomarker, vital signs (wearables), DNA, electronic health records, and other information.

“The medical industry is undergoing a dramatic and systemic change, giving consumers and their physicians a powerful tool built upon cognitive learning and Watson will make the change even more transformative,” said Michael Nova, M.D., Chief Medical Officer, Pathway Genomics; and Member of Watson Advisory Board. “IBM is viewed worldwide as forward thinking pioneers in the development of electronic knowledge, and also sets gold standard in the industry for the delivery of that knowledge.  We are fortunate to team with them as we enter this new era of cognitive medicine.”

“By tapping into IBM Watson’s cognitive computing capabilities, Pathway Genomics is allowing consumers to ask health related questions, in their own words and receive personalized and relevant responses,” said Stephen Gold, Vice President, IBM Watson Group. “Cognitive computing solutions based on Watson’s transformative technology will help define how consumers and businesses alike make better informed lifestyle decisions, enabling better outcomes.”

In January, the Watson Group announced to advance new cognitive computing capabilities. IBM is investing $100 million to spur innovation for entrepreneurial organizations – ranging from start-ups and VC-backed companies to established players – who, like Pathway Genomics, are collectively bringing forward a new generation of apps and solutions infused with Watson’s cognitive computing capabilities.

IBM Watson: Pioneering a New Era of Computing

IBM Watson represents a new era of computing in which third party apps and systems will interact with human users more naturally, augment our knowledge with Big Data insights, and learn to improve how they assist us.  

Fueled by innovation from a mission to transform industries and professions, Watson is uniquely positioned at the forefront of the new era of computing, evidenced by an unmatched demonstration of what cognitive systems can bring to transform decision-making. IBM is delivering a range of cloud-based products and services to clients in industries such as banking, healthcare, insurance, retail and education.  

IBM is investing $1 billion into the Watson Group, focusing on development and research and bringing cloud-delivered cognitive applications and services to market. This includes $100 million available for venture investments to support IBM’s ecosystem of start-ups and businesses building cognitive apps made with Watson.

To learn more about this announcement, visit IBM’s Smarter Planet Blog: http://ibm.co/1pNDHxY

For more information on IBM Watson, visit: www.ibmwatson.com

To join the social discussion about Watson, include the hashtag #ibmwatson. Follow Watson on Facebook and see Watson on YouTube and Flickr.

Check out the IBM Watson press kit at: http://www-03.ibm.com/press/us/en/presskit/27297.wss

About Pathway Genomics Corporation

As a CLIA and CAP accredited clinical laboratory based in San Diego, California, Pathway Genomics provides physicians and their patients with actionable and accurate genetic information to improve or maintain health and wellness. Since its founding in 2008, Pathway Genomics has become known for its dedication to innovation and commitment to medical responsibility – making it a leader in the commercial genetic testing and healthcare Big Data industry. Pathway Genomics’ testing services cover a variety of conditions including cancer risk, cardiac health, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health. For more about Pathway Genomics, visit www.pathway.com.

Press Contact(s)John Connolly IBM Media Relations781-636-8512jconnol@us.ibm.com

Zak PughPathway Genomics Media Relations858-217-4358zak.pugh@pathway.com

Logo – http://photos.prnewswire.com/prnh/20090416/IBMLOGO
SOURCE IBM

Sorrento To Present At The 2014 Stifel Healthcare Conference

November 12, 2014 – 9:00 am | Edit Post

SAN DIEGO, Nov. 12, 2014 /PRNewswire/ – Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), today announced that Dr. Henry Ji, President and Chief Executive Officer, will present on Tuesday, November 18, 2014 at 3:00 pm ET in the Winslow Room at the New York Palace Hotel in New York City.

About Sorrento Therapeutics, Inc. 

Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento’s most advanced asset Cynviloq™, the next-generation paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated antibody drug conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento’s strategy is to enable a multi-pronged approach to combating cancer with small molecules, mono- and bi-specific therapeutic antibodies, and ADCs.
SOURCE Sorrento Therapeutics, Inc.

Trovagene to Present at Upcoming Healthcare Conferences

November 12, 2014 – 6:15 am | Edit Post

SAN DIEGO, Nov. 12, 2014 /PRNewswire/ – Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to present a corporate overview at the following 2014 healthcare conferences: the Stifel 2014 Healthcare Conference and the Canaccord Genuity Medical Technologies and Diagnostics Forum. Each presentation will be webcast, and replays of each will be available at www.trovagene.com and archived for 90 days.

Stifel 2014 Healthcare Conference

Trovagene is scheduled to present at the Stifel 2014 Healthcare Conference, taking place at The New York Palace Hotel, New York, on Wednesday, November 19, at 10:20 a.m. EST. The presentation will be webcast live at http://www.veracast.com/webcasts/stifel/healthcare2014/39205522246.cfm and can also be accessed through the investor relations page at www.trovagene.com.

Canaccord Genuity Medical Technologies and Diagnostics Forum

Trovagene is scheduled to present at the Canaccord Genuity Medical Technologies and Diagnostics Forum 2014 at the Westin Grand Central in New York, on Thursday, November 20, at 2:00 p.m. EST. The presentation will be webcast live at http://www.wsw.com/webcast/canaccord16 and can also be accessed through the investor relations page at www.trovagene.com.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Contact

Investor Relations

Media Relations

David Moskowitz and Amy Caterina

Investor Relations

Ian Stone

Account Director

Trovagene, Inc.

Canale Communications, Inc.

858-952-7593

619-849-5388

ir@trovagene.com

ian@canalecomm.com

Logo – http://photos.prnewswire.com/prnh/20120620/LA28014LOGO
SOURCE Trovagene, Inc.

Veracyte Announces Appointment of John L. Bishop to Its Board of Directors Following the Resignation of Samuel D. Colella

November 12, 2014 – 5:30 am | Edit Post

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2014 /PRNewswire/ – Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced the resignation of Samuel D. Colella from its Board of Directors, effective November 30, 2014. The Veracyte Board accepted his resignation at its November 11, 2014 meeting, during which it also approved the selection of veteran diagnostics executive John L. Bishop to fill the vacancy left by Mr. Colella, effective December 1, 2014. Mr. Bishop will also join the Board’s Compensation Committee.

“On behalf of Veracyte, I would like to thank Sam for his years of service and significant contributions as a member of the founding Veracyte Board,” said Bonnie H. Anderson, president and chief executive officer. “His guidance and depth of insight into the challenges and opportunities that emerging growth companies face have been invaluable to the company. He will be greatly missed.”

Mr. Bishop has a distinguished career in diagnostics and the life sciences industry. He currently serves as chairman and chief executive officer of Cepheid, a leading global molecular diagnostics company, which he joined in 2002. Prior to that, he was president and chief executive officer of Vysis, Inc., a genomic disease management company that was acquired by Abbott Laboratories. From 1991 until 1993, Mr. Bishop was chairman and chief executive officer of MicroProbe Corporation, a biotechnology company, and from 1987 until 1991, of Source Scientific Systems, a biomedical instrument manufacturing company. Prior to that, from 1984 to 1986, he was president and chief operating officer of Gen-Probe, Inc., a molecular diagnostics company. Mr. Bishop served as a director of Conceptus, Inc., a medical device company, from February 2009 until June 2013 when it was acquired by Bayer HealthCare LLC.  He has been a member of the AdvaMedDx Board, a medical diagnostics industry advocacy group, since 2010 and was elected chairman in December 2013.

“We are delighted to have John join our team,” said Ms. Anderson. “His tremendous industry experience and insights, built over 30 years, will be instrumental as we continue to grow our business by delivering genomic solutions that improve patient care and take costs out of the healthcare system.”

About Veracyte

Veracyte (Nasdaq: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s first commercial solution, the Afirma® Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis and is becoming a new standard of care in thyroid nodule assessment. Since launching its Afirma solution in 2011, Veracyte estimates it has helped approximately 10,000 patients with thyroid nodules avoid unnecessary surgery, reducing healthcare costs by millions of dollars. Afirma is recommended in leading practice guidelines and is covered for more than 135 million lives in the United States, including through Medicare and most commercial insurance plans. Veracyte intends to expand its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. The company is in late product development for a genomic test to resolve preoperative ambiguity in lung nodules that are suspicious for cancer. Veracyte is also developing a second product in pulmonology, targeting interstitial lung diseases that include idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our limited operating history and history of losses; our ability to increase usage of and reimbursement for Afirma and any future products we may develop or sell; our ability to continue our momentum and growth; our dependence on a few payers for a significant portion of our revenue; the complexity, time and expense associated with billing and collecting from payers for our test; laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; our dependence on strategic relationships and our ability to successfully convert new accounts resulting from such relationships; our ability to develop and commercialize new products and the timing of commercialization; our ability to achieve sales penetration in complex commercial accounts; the occurrence and outcome of clinical studies; the timing and publication of study results; the applicability of clinical results to actual outcomes; our inclusion in clinical practice guidelines; the continued application of clinical guidelines to our products; our ability to compete; our ability to expand into international markets; our ability to obtain capital when needed; and other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.  

Veracyte, Afirma, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.

Media:Tracy Morris650-380-4413 Tracy.Morris@Veracyte.com

Investors:Angeli KolhatkarBurns McClellan, Inc.212-213-0006akolhatkar@burnsmc.com
SOURCE Veracyte

Veracyte Announces Appointment of John L. Bishop to Its Board of Directors Following the Resignation of Samuel D. Colella

November 12, 2014 – 5:30 am | Edit Post

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2014 /PRNewswire/ – Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced the resignation of Samuel D. Colella from its Board of Directors, effective November 30, 2014. The Veracyte Board accepted his resignation at its November 11, 2014 meeting, during which it also approved the selection of veteran diagnostics executive John L. Bishop to fill the vacancy left by Mr. Colella, effective December 1, 2014. Mr. Bishop will also join the Board’s Compensation Committee.

“On behalf of Veracyte, I would like to thank Sam for his years of service and significant contributions as a member of the founding Veracyte Board,” said Bonnie H. Anderson, president and chief executive officer. “His guidance and depth of insight into the challenges and opportunities that emerging growth companies face have been invaluable to the company. He will be greatly missed.”

Mr. Bishop has a distinguished career in diagnostics and the life sciences industry. He currently serves as chairman and chief executive officer of Cepheid, a leading global molecular diagnostics company, which he joined in 2002. Prior to that, he was president and chief executive officer of Vysis, Inc., a genomic disease management company that was acquired by Abbott Laboratories. From 1991 until 1993, Mr. Bishop was chairman and chief executive officer of MicroProbe Corporation, a biotechnology company, and from 1987 until 1991, of Source Scientific Systems, a biomedical instrument manufacturing company. Prior to that, from 1984 to 1986, he was president and chief operating officer of Gen-Probe, Inc., a molecular diagnostics company. Mr. Bishop served as a director of Conceptus, Inc., a medical device company, from February 2009 until June 2013 when it was acquired by Bayer HealthCare LLC.  He has been a member of the AdvaMedDx Board, a medical diagnostics industry advocacy group, since 2010 and was elected chairman in December 2013.

“We are delighted to have John join our team,” said Ms. Anderson. “His tremendous industry experience and insights, built over 30 years, will be instrumental as we continue to grow our business by delivering genomic solutions that improve patient care and take costs out of the healthcare system.”

About Veracyte

Veracyte (Nasdaq: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s first commercial solution, the Afirma® Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis and is becoming a new standard of care in thyroid nodule assessment. Since launching its Afirma solution in 2011, Veracyte estimates it has helped approximately 10,000 patients with thyroid nodules avoid unnecessary surgery, reducing healthcare costs by millions of dollars. Afirma is recommended in leading practice guidelines and is covered for more than 135 million lives in the United States, including through Medicare and most commercial insurance plans. Veracyte intends to expand its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. The company is in late product development for a genomic test to resolve preoperative ambiguity in lung nodules that are suspicious for cancer. Veracyte is also developing a second product in pulmonology, targeting interstitial lung diseases that include idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our limited operating history and history of losses; our ability to increase usage of and reimbursement for Afirma and any future products we may develop or sell; our ability to continue our momentum and growth; our dependence on a few payers for a significant portion of our revenue; the complexity, time and expense associated with billing and collecting from payers for our test; laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; our dependence on strategic relationships and our ability to successfully convert new accounts resulting from such relationships; our ability to develop and commercialize new products and the timing of commercialization; our ability to achieve sales penetration in complex commercial accounts; the occurrence and outcome of clinical studies; the timing and publication of study results; the applicability of clinical results to actual outcomes; our inclusion in clinical practice guidelines; the continued application of clinical guidelines to our products; our ability to compete; our ability to expand into international markets; our ability to obtain capital when needed; and other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.  

Veracyte, Afirma, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.

Media:Tracy Morris650-380-4413 Tracy.Morris@Veracyte.com

Investors:Angeli KolhatkarBurns McClellan, Inc.212-213-0006akolhatkar@burnsmc.com
SOURCE Veracyte

Tandem Diabetes Care Expands Diabetes Data Management Access With Partnership

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 12, 2014 /PRNewswire/ — Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim Insulin Pump, announced today that the t:slim Pump is now compatible with diasend Clinic, a web-based diabetes data management tool developed by Diasend. Healthcare providers…

MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) To Present At Healthcare Conference

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 12, 2014 /PRNewswire/ — MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare…

Batu Biologics Recruits Inventor Of Licensed University of California, San Diego (UCSD) Cancer Immunotherapy To Scientific Advisory Board

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Batu Biologics, an immunotherapy company developing the ValloVax anti-angiogenic lung cancer vaccine, announced today the addition Dr. Davorka Messmer to its Scientific Advisory Board (SAB).Dr. Messmer will accelerate the clinical development of the companys cancer vaccine platform, which trains the immune system to selectively destroy the tumor-associated…

TrovaGene, Inc. To Present At Upcoming Healthcare Conferences

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 12, 2014 /PRNewswire/ –Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to present a corporate overview at the following 2014 healthcare conferences: the Stifel 2014 Healthcare Conference…